menu
    • menu

    Company profile for Mezzion Pharma Co Ltd

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mezzion Inc. is a company specialized in global new drug development process that generates profit through identifying new candidate drugs, developing the new drug up to a certain level in clinical trials (generally up to phase 2 and licensing-out to a suitable partner, operating based on a new business model with profits from up-front payment, milestone payment, and royalty.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mezzion Pharma Co Ltdkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    7F, Seokcheon Building, 570 Samseong?ro, Seoul 06163
    Telephone
    Telephone
    02-560-8008
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.mezzion.co.kr/eng/index.asp
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mezzion-pharma-co-ltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mezzion Bolsters Udenafil Exclusivity In Fontan Patients
    Mezzion Bolsters Udenafil Exclusivity In Fontan Patients

    03 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-announces-us-patent-allowance-strengthening-udenafil-exclusivity-in-fontan-patients-302631809.html

    PR NEWSWIRE
    03 Dec 2025
    Share Share
    Udenafil Boosts Exercise Capacity In Fontan Patients Fuel Trial
    Udenafil Boosts Exercise Capacity In Fontan Patients Fuel Trial

    12 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/post-hoc-fuel-trial-analysis-shows-udenafil-significantly-improves-exercise-capacity-in-fontan-patients-with-reduced-baseline-function-302528103.html

    PR NEWSWIRE
    12 Aug 2025
    Share Share
    Mezzion Gets $20 M to Advance Udenafil for Fontan Patients
    Mezzion Gets $20 M to Advance Udenafil for Fontan Patients

    13 Jun 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/mezzion-secures-20-million-funding-to-advance-phase-3-clinical-development-of-udenafil-for-fontan-patients-17273

    INDPHARMAPOST
    13 Jun 2025
    Share Share
    Mezzion Expands Udenafil Pipeline to Target ADPKD Kidney Market
    Mezzion Expands Udenafil Pipeline to Target ADPKD Kidney Market

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-expands-udenafil-pipeline-to-adpkd-to-target-multi-billion-dollar-kidney-disease-market-302479282.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share
    New ICD-10 Codes Recognize Fontan-Associated Conditions
    New ICD-10 Codes Recognize Fontan-Associated Conditions

    16 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-icd-10-codes-recognize-fontan-associated-conditions-advancing-care-and-coverage-for-rare-congenital-heart-disease-community-302430453.html

    PR NEWSWIRE
    16 Apr 2025
    Share Share
    Mezzion Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
    Mezzion Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2

    01 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mezzion-pharmaceuticals-announces-dr-rahul-rathod-of-boston-childrens-hospital-and-harvard-medical-school-as-the-global-principal-investigator-for-the-confirmatory-pivotal-phase-3-trial-fuel-2-302077629.html

    PR NEWSWIRE
    01 Mar 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search